Patients battling an incurable blood cancer could live significantly longer without their disease progressing, thanks to a new once-daily pill that may soon be added to existing NHS treatments, researchers have revealed.
A recent trial demonstrated that individuals receiving a 'triplet therapy', which incorporated the novel drug mezigdomide, experienced more than double the progression-free survival time.
